Skip header and navigation

1 records – page 1 of 1.

[Neuroendocrine tumours of the GI tract--data from the German NET Registry].

https://arctichealth.org/en/permalink/ahliterature262016
Source
Zentralbl Chir. 2014 Jun;139(3):276-83
Publication Type
Article
Date
Jun-2014
Author
N. Begum
S. Maasberg
U. Plöckinger
M. Anlauf
A. Rinke
G. Pöpperl
H. Lehnert
J R Izbicki
M. Krausch
Y K Vashist
A. Raffel
C G Bürk
J. Hoffmann
P. Goretzki
U F Pape
Source
Zentralbl Chir. 2014 Jun;139(3):276-83
Date
Jun-2014
Language
German
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Aged, 80 and over
Combined Modality Therapy
Digestive System Neoplasms - diagnosis - pathology - surgery
Female
Follow-Up Studies
Hormones, Ectopic - blood
Humans
Male
Middle Aged
Neoplasm Grading
Neuroendocrine Tumors - diagnosis - pathology - surgery
Prognosis
Registries
Syndrome
Young Adult
Abstract
Neuroendocrine tumours (NET) are rare and heterogeneous neoplasia. To obtain valid data on epidemiology, diagnostics, therapy, prognosis and risk factors is the aim of the German NET registry.
Data from 2009 histologically proven NET were collected from 35 NET centres between 1999 and 2010. Data collection has been performed prospectively since 2004. Results: Median follow-up was 34.5 months and median age at diagnosis 56.4 years. Primary tumour localisations were pancreas (34.2%), midgut (5.8%), stomach (6.5%), bowel (6.9%), duodenum (4.8%) and neuroendocrine CUP (12.6%). Synchronous metastases were seen in 46% and second malignancies in 12%. From 860 patients, 402 (46.7%) had functional tumours with the following hormone excess syndromes: carcinoid syndrome (19.1%; n = 164), persistent hyperinsulinaemic hypoglycaemia (17.7%; n = 152), Zollinger- Ellison syndrome (7.1%; n = 61), glucagonoma (0.7%; n = 15), Verner-Morrison syndrome (0.4%; n = 8) and somatostatinoma syndrome(0.1%; n = 2). Surgical therapy was performed in 78%, therapy with somatostatin receptor analogues(SSA) in 28%, peptide radioreceptor therapy (PRRT) in 19%, chemotherapy in 18% and interferon therapy in 6.5%. Only surgery was done in 47%, whereas 53% received a second therapy. General mortality rate during follow-up was 14.9%. The tumour-specific survival rates for 2, 5 and 10 years were 94, 85 and 70%. The 5-year survival is dependent on the surgical or non-surgical therapy (82 versus 61%, p
PubMed ID
23042103 View in PubMed
Less detail